Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.53 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11884926 | 0.86 | SLC6A4 (0.54) | SLC6A4MRGPRX4PTGER1HTR2CHTR2B | |
| SCHEMBL7013006 | 0.85 | CYP1A2 (0.69) | CYP2C9CYP1A2CYP3A4CYP2C19MRGPRX4 | |
| SCHEMBL12505360 | 0.84 | MRGPRX4 (0.55) | CYP2C9CYP1A2CYP3A4CYP2C19SLC6A4 | |
| SCHEMBL13812974 | 0.83 | HTR2C (0.56) | CYP2C9CYP1A2CYP3A4CYP2C19SLC6A4 | |
| SCHEMBL6430443 | 0.83 | PTGER1 (0.53) | CYP2C9SLC6A4MRGPRX4PTGER1LTA4H | |
| SCHEMBL11372714 | 0.82 | MAPT (0.56) | MAPTHTTAPPLTA4HMAPK14 | |
| SCHEMBL11114770 | 0.81 | MAOB (0.59) | CYP1A2CYP3A4CYP2C19LMNAMAPT | |
| SCHEMBL8057639 | 0.81 | LMNA (0.52) | CYP1A2CYP2C19LMNAMAPTAPP | |
| SCHEMBL1196687 | 0.80 | CCR5 (0.64) | SLC6A4MRGPRX4PTGER1STAT3 | |
| SCHEMBL3133767 | 0.80 | LTA4H (0.55) | MAPTAPPLTA4HMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067600-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | UNIVERSITY OF KANSAS (US) | 2024-02-29 | — | — | US | disclosed |
| US-20220396547-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | UNIV KANSAS (US) | 2022-12-15 | — | — | US | disclosed |
| US-10865181-B2 | Small molecule inhibitors of the mitochondrial permeability transition pore (mtPTP) | UNIVERSITY OF KANSAS (US) | 2020-12-15 | — | — | US | disclosed |
| US-20180282264-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | UNIVERSITY OF KANSAS | 2018-10-04 | — | — | US | disclosed |
| EP-3215152-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | The University of Kansas (US) | 2017-09-13 | — | — | EP | disclosed |
| US-9550746-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550746-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550746-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| WO-2016073633-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | UNIVERSITY OF KANSAS (US) | 2016-05-12 | — | — | WO | disclosed |
| US-20150218119-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2015-08-06 | — | — | US | disclosed |
| US-20130231338-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231338-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20080275053-A1 | Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid | GLAXOSMITHKLINE | 2008-11-06 | — | — | US | disclosed |
| US-20080275053-A1 | Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid | GLAXOSMITHKLINE | 2008-11-06 | — | — | US | disclosed |
| US-20080275053-A1 | Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid | GLAXOSMITHKLINE | 2008-11-06 | — | — | US | disclosed |
| EP-1670756-A1 | HETEROCYCLYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005037786-A1 | HETEROCYCLYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
| US-5179111-A | IMIDAZOLE DERIVATIVES | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-01-12 | — | — | US | disclosed |
| EP-0323799-B1 | IMIDAZOLE DERIVATIVES II | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-11-11 | — | — | EP | disclosed |
| EP-0323799-A1 | Imidazole derivatives II | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067600-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | MTCH2, TIMM50, TIMM10 | CYP2C9 1776/4885CYP1A2 2048/4885CYP3A4 1451/4885 |
| US-20220396547-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | MTCH2, TIMM50, TIMM10 | CYP2C9 1776/4885CYP1A2 2048/4885CYP3A4 1451/4885 |
| US-20150218119-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CCR5 | CYP2C9 2009/4885CYP1A2 2582/4885CYP3A4 1905/4885 |
| US-20080275053-A1 | Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid | PTGER1, PTGER2, PTGDR | CYP2C9 820/4885CYP1A2 384/4885CYP3A4 1749/4885 |
| US-20180282264-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | MTCH2, TIMM50, TIMM10 | CYP2C9 1776/4885CYP1A2 2048/4885CYP3A4 1451/4885 |
| US-20130231338-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CCR5 | CYP2C9 2009/4885CYP1A2 2582/4885CYP3A4 1905/4885 |
| US-10865181-B2 | Small molecule inhibitors of the mitochondrial permeability transition pore (mtPTP) | MTCH2, TIMM50, TIMM10 | CYP2C9 1776/4885CYP1A2 2048/4885CYP3A4 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.